

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **December 16, 2015**

**LEXARIA CORP.**

(Exact name of registrant as specified in its charter)

---

**Nevada**

(State or other jurisdiction of  
incorporation)

**000-52138**

(Commission File Number)

**20-2000871**

(IRS Employer  
Identification No.)

---

**#950 – 1130 West Pender Street, Vancouver, BC Canada**

(Address of principal executive offices)

**V6E 4A4**

(Zip Code)

Registrant's telephone number, including area code **(604) 602-1675**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 5.03 Amendments to Articles of Incorporation or Bylaws****Item 8.01 Other Items**

On November 24, 2015, our board of directors approved a forward stock split of our authorized and issued and outstanding shares of common stock on a basis of 1 old share of common stock for 1.1 new shares of common stock. Upon effect of the forward stock split our authorized capital will increase 220,000,000 shares of common stock, par value \$0.001 and our issued and outstanding shares will increase from 39,952,984 to 43,948,286 shares of common stock, with a par value of \$0.001.

The reverse stock split has been reviewed by the Financial Industry Regulatory Authority ("FINRA") and the Canadian Securities Exchange ("CSE") have been approved for filing with an effective date of December 16, 2015.

The forward split will become effective with the OTC Markets at the opening of trading on December 16, 2015 under the symbol "LXRPD". The "D" will be placed on our ticker symbol for 20 business days. Our new CUSIP number is 52886N307.

**Item 7.01 Regulation FD Disclosure.**

A copy of the news release announcing Lexaria announcing forward split filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

**Item 9.01 Financial Statements and Exhibits**

[3.1](#) [Certificate of Change filed with the Nevada Secretary of State on December 15, 2015 with an effective date of December 16, 2015](#)

[99.1](#) [Press Release dated December 16, 2015](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LEXARIA CORP.**

\_\_\_\_\_  
**Chris Bunka**  
CEO

Date: December 16, 2015

---



BARBARA K. CEGAVSKE  
Secretary of State  
202 North Carson Street  
Carson City, Nevada 89701-4201  
(775) 684-5708  
Website: www.nvssa.gov



\*09303\*

**Certificate of Change Pursuant  
to NRS 78.209**

Filed in the office of <i>Barbara K. Cegavske</i> Barbara K. Cegavske Secretary of State State of Nevada	Document Number <b>20150544845-68</b> Filing Date and Time <b>12/14/2015 2:01 PM</b> Entity Number <b>C33051-2004</b>
--	--

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

**Certificate of Change filed Pursuant to NRS 78.209  
For Nevada Profit Corporations**

1. Name of corporation:  
Lexaria Corp.

2. The board of directors have adopted a resolution pursuant to NRS 78.209 and have obtained any required approval of the stockholders.

3. The current number of authorized shares and the par value, if any, of each class or series, if any, of shares before the change:  
200,000,000 shares of common stock with a par value of \$0.001

4. The number of authorized shares and the par value, if any, of each class or series, if any, of shares after the change:  
220,000,000 shares of common stock with a par value of \$0.001

5. The number of shares of each affected class or series, if any, to be issued after the change in exchange for each issued share of the same class or series:  
The corporation shall issue 1.1 shares of common stock for every one (1) share of common stock issued and outstanding immediately prior to the effective date of the stock split.

6. The provisions, if any, for the issuance of fractional shares, or for the payment of money or the issuance of scrip to stockholders otherwise entitled to a fraction of a share and the percentage of outstanding shares affected thereby:  
No fractional shares shall be issued. Fractional shares shall be rounded up.

7. Effective date and time of filing: (optional) Date: December 16, 2015 Time:

8. Signature: (required) (must not be later than 90 days after the certificate is filed)

X   
Signature of Officer

Chief Executive Officer  
Title

**IMPORTANT:** Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

This form must be accompanied by appropriate fees.  
W0290450

Nevada Secretary of State Stock Split  
Revised: 1-9-15

---

## Lexaria Forward Stock Split

KELOWNA, BC-- December 16, 2015 - Lexaria Corp. (OTCQB: LXRPD) (CNSX: LXX) (the "Company" or "Lexaria") confirms the earlier announced Lexaria forward stock split has taken place and the company's shares begin trading on a post-split basis today at the open of trading.

On November 24, 2015, our board of directors approved a forward stock split of our authorized and issued and outstanding shares of common stock on a basis of 1 old share of common stock for 1.1 new shares of common stock. Upon effect of the forward stock split our authorized capital will increase to 220,000,000 shares of common stock, par value \$0.001.

The reverse stock split has been reviewed by the Financial Industry Regulatory Authority ("FINRA") and the Canadian Securities Exchange ("CSE") and has been approved for filing with an effective date of December 16, 2015. The Company's trading symbol on the Canadian Securities Exchange remains unchanged: LXX.

The forward split is effective with the OTC Markets at the opening of trading on December 16, 2015 under the symbol "LXRPD". The "D" will be placed on our ticker symbol for 20 business days, and then the trading symbol will revert back to LXRP. Our new CUSIP number is 52886N307.

Lexaria thanks its shareholders for their continued support and will in the future provide information at an appropriate time if our board of directors should decide at some point in the future to once again effect a forward stock split of the company's shares.

### About Lexaria

Lexaria is a food sciences company, with common shares quoted in the USA with symbol LXRP and in Canada with symbol LXX. The Company uses innovative technology to deliver unique food experiences. [www.lexarienergy.com](http://www.lexarienergy.com)

### FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.  
Chris Bunka  
Chairman & CEO  
(250) 765-6424

### FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: the provision of any significant investor relations or media relations services. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the medical marijuana, hemp oil sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company's needs or that it will not need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. There is no assurance that any patent application in the USA or any other nation or under any treaty will result in the award of an actual patent; nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova™ products and Lexaria Energy products are not intended to diagnose, treat, cure or prevent any disease.

*The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*

---